(0.31%) 5 115.81 points
(0.30%) 38 356 points
(0.35%) 15 984 points
(-0.99%) $83.02
(5.25%) $2.02
(0.29%) $2 354.10
(0.36%) $27.63
(4.12%) $960.05
(-0.27%) $0.932
(-0.47%) $10.97
(-0.58%) $0.796
(1.66%) $93.40
Live Chart Being Loaded With Signals
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea...
Stats | |
---|---|
本日の出来高 | 47.92M |
平均出来高 | 60.79M |
時価総額 | 57.67M |
EPS | $0 ( 2024-04-01 ) |
次の収益日 | ( $0 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.120 |
ATR14 | $0.00100 (0.48%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Chaturvedi Pravin R | Buy | 134 | Common Stock |
2024-04-05 | Chaturvedi Pravin R | Sell | 134 | Restricted stock units |
2024-04-05 | Wolin Jonathan S. | Buy | 89 | Common Stock |
2024-04-05 | Wolin Jonathan S. | Sell | 89 | Restricted stock units |
2024-04-05 | Lizak Carol R. | Buy | 60 | Common Stock |
INSIDER POWER |
---|
80.51 |
Last 99 transactions |
Buy: 3 516 210 | Sell: 493 473 |
ボリューム 相関
Jaguar Health Inc 相関
10 最も負の相関 | |
---|---|
IVCP | -0.983 |
MSDA | -0.982 |
VLAT | -0.982 |
HERA | -0.982 |
FICV | -0.982 |
PRLH | -0.981 |
ACQR | -0.98 |
CRZN | -0.98 |
AGGR | -0.979 |
CREC | -0.979 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Jaguar Health Inc 相関 - 通貨/商品
Jaguar Health Inc 財務諸表
Annual | 2023 |
収益: | $9.76M |
総利益: | $5.34M (54.67 %) |
EPS: | $-1.790 |
FY | 2023 |
収益: | $9.76M |
総利益: | $5.34M (54.67 %) |
EPS: | $-1.790 |
FY | 2022 |
収益: | $11.96M |
総利益: | $9.94M (83.11 %) |
EPS: | $-36.18 |
FY | 2021 |
収益: | $4.34M |
総利益: | $2.00M (46.18 %) |
EPS: | $-294.27 |
Financial Reports:
No articles found.
Jaguar Health Inc
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。